Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959983 | 1.00 | MAPT (0.68) | MAPTALDH1A1HCAR2FAAHCYP4F2 | |
| SCHEMBL27925927 | 0.98 | MAPT (0.66) | MAPTALDH1A1HCAR2FAAHCYP4F2 | |
| SCHEMBL10015549 | 0.98 | MAPT (0.66) | MAPTALDH1A1HCAR2FAAHCYP4F2 | |
| SCHEMBL29131601 | 0.94 | MAPT (0.70) | MAPTALDH1A1HCAR2FAAHCYP4F2 | |
| SCHEMBL17679310 | 0.94 | MAPT (0.70) | MAPTALDH1A1HCAR2FAAHCYP4F2 | |
| SCHEMBL22100454 | 0.88 | MAPT (0.85) | MAPTALDH1A1HCAR2FAAHCYP3A4 | |
| SCHEMBL27487508 | 0.86 | MAPT (0.70) | MAPTALDH1A1HCAR2FAAHALOX15 | |
| SCHEMBL872985 | 0.86 | MAPT (0.70) | MAPTALDH1A1HCAR2FAAHALOX15 | |
| SCHEMBL872986 | 0.86 | MAPT (0.70) | MAPTALDH1A1HCAR2FAAHALOX15 | |
| SCHEMBL28309024 | 0.86 | MAPT (0.51) | MAPTALDH1A1HCAR2FAAHCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-03-06 | — | — | US | disclosed |
| WO-2022159644-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | disclosed |
| EP-2217589-A2 | MODULATORS OF OCULAR OXIDATIVE STRESS | ReVision Therapeutics, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090253745-A1 | MODULATORS OF OCULAR OXIDATIVE STRESS | SIRION THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009070693-A2 | MODULATORS OF OCULAR OXIDATIVE STRESS | SIRION THERAPEUTICS, INC (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253745-A1 | MODULATORS OF OCULAR OXIDATIVE STRESS | GPX4, GPX1, ALDH1A2 | MAPT 2604/4885ALDH1A1 235/4885HCAR2 1193/4885 |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | MAPT 4347/4885ALDH1A1 769/4885HCAR2 1813/4885 |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | FOXM1, MDM2, FOXO1 | MAPT 4116/4885ALDH1A1 620/4885HCAR2 1476/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | MAPT 2740/4885ALDH1A1 1320/4885HCAR2 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.